Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2014 - 2026)

Rocket Pharmaceuticals has disclosed Income from Continuing Operations across 13 years of filings, most recently posting 48823000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 48823000.0, up 23.14% year-over-year; the trailing twelve-month figure through Mar 2026 was 215719000.0 (up 18.76% YoY), and the FY2025 annual result was 230420000.0, up 13.64% from the prior year.
• Income from Continuing Operations came in at 48823000.0 for Q1 2026 at Rocket Pharmaceuticals, down from 43746000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 42405000.0 in Q1 2022 to a low of 71889000.0 in Q2 2024.
• The 5-year median for Income from Continuing Operations is 62935000.0 (2023), against an average of 60272235.29.
• Across the five-year window, Income from Continuing Operations tumbled 59.79% in 2022 and gained 28.93% in 2025, its largest moves.
• Rocket Pharmaceuticals' Income from Continuing Operations stood at 68304000.0 in 2022, then increased by 7.86% to 62935000.0 in 2023, then increased by 2.2% to 61550000.0 in 2024, then increased by 28.93% to 43746000.0 in 2025, then slipped by 11.61% to 48823000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 48823000.0 (Q1 2026), 43746000.0 (Q4 2025), and 52011000.0 (Q3 2025), per Business Quant data.